MediRama

Contact us LinkedIn

Resources

Share recent publications on regulatory trends, FDA programs, and oncology clinical trial
strategies, such as articles by MediRama's team on oncology drug development.

Total 118

View More

[Edge Column] The Evolution of Multiple Myeloma Treatment and J&J’s Contributions

  • 2026.04.08
  • Souce: THE BIO
View More

[EDGE Column] The Evolution of Companion Diagnostics in Oncology Drug Development

  • 2026.04.08
  • Souce: THE BIO
View More

An Analysis of the Companion Diagnostic Approval Case That Helped Make Keytruda a Blockbuster

  • 2026.02.27
  • Souce: HITNEWS
View More

[EDGE Column] FDA Clinical Pharmacology Review Trends and Regulatory Implications for ADC Development

  • 2026.02.10
  • Souce: THE BIO
View More

MediRama’s Analysis of the Characteristics of 13 ADCs Approved by the U.S. FDA Published in an International Academic Journal

  • 2026.01.26
  • Souce: Hankyung Bio Insight
View More

MediRama published a paper in TCP Analyzing FDA Review Documents for Approved ADCs

  • 2026.01.15
  • Souce: THE BIO
View More

MediRama and the Korea Drug Research Association Successfully Conclude ‘Oncology Drug Development Strategy Training’

  • 2025.10.22
  • Souce: THE BIO
View More

BIX 2025: What ‘radical’ changes in US, China mean for bio sector

  • 2025.10.22
  • Souce: BioWorld
View More

[GCCL Special Contribution ②] The Significance of the FDA’s Oncology Expedited Review System and Its Strategic Utilization

  • 2025.09.23
  • Souce: THE BIO
View More

[GCCL Special Contribution ①] The Significance of the FDA’s Oncology Expedited Programs and Their Strategic Utilization

  • 2025.09.19
  • Souce: THE BIO